Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma
Long-term benefit seen for relapse-free survival in stage III disease with BRAF V600E, V600K mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.